European registry of patients with the coronavirus (Covid-19)
In order to provide patients with the coronavirus (Covid-19) and with cardiovascular complications with the best possible care, we want to know how we can best treat these patients. That is why partners of the Dutch CardioVascular Alliance have launched CAPACITY. CAPACITY is a registry of patients with the coronavirus (Covid-19) within Europe. The aim of CAPACITY is to collect data regarding the cardiovascular history, diagnostic information and occurrence of cardiovascular complications in patients with the coronavirus. How can you contribute and help the CAPACITY team? View the CAPACITY website.
- Heart failure
- Cerral Ischemia
- High risks (hypertension, diabetes and atherosclerosis)
Expertise centers for rare diseases
Four out of the 21 centers are connected to Circulatory Health:
• Center for Congenital Vascular Abnormalities Utrecht.
• Center for Hereditary Cardiovascular Diseases.
• WKZ Children's Heart Center (in collaboration with Child Health).
• National Expertise Center PXE (LEP).
- Group Asselbergs
- Group Blankestijn
- Group Chamuleau
- Group Kappelle
- Group de Kleijn
- Department of medical physiology
- Group Pasterkamp
- Group van Rooij
- Group Ruigrok
- Group den Ruijter
- Group van der Schouw
- Group Sluijter
- Group Teske
- Group Visseren
The Circulatory Health program created significant societal impact with the spin-off company Julius Clinical. This academic research organization conducts national and international phase IIb-IV clinical trials. Since 2007, over 50 trials across more than 700 sites globally have been carried out.
Julius Clinical is not a traditional contract research organization. Our academic roots guarantee independence and secure trust from patients, doctors and society as a whole. The company insists on independently analyzing and reporting of the data.
Three of the largest and most prestigious projects are the Alecardio project, the CAPITA trial and the Advance-project. The Alecardio trial tests the effect of aleglitazar in about 7,000 patients with type 2 diabetes who experienced a recent acute coronary syndrome event.
The CAPITA trial establishes the efficacy of a pneumococcal vaccine in preventing a first episode of community acquired pneumonia. In the Advance project, routine antihypertensive therapy and glucose control therapy was compared in 11,000 type 2 diabetes patients.
Chair Center for Circulatory Health
Prof.dr. Folkert W. Asselbergs
Prof.dr. Folkert W. Asselbergs is Prof in cardiovascular genetics and consultant cardiologist at the department of Cardiology, UMC Utrecht. He is chair of the program committee of the Center for Circulatory Health .
Center for Circulatory Health of UMC Utrecht receives unique European accreditation
Overview news items
Highlight: Magazine Circulatory Health
In this magazine various aspects of the research and care in the field of cardiovascular diseases in the UMC Utrecht are highlighted.
The Utrecht Cardiovascular Cohort
The Utrecht Cardiovascular Cohort: Uniform data collection in routine clinical practice in cardiovascular patients for optimal care, quality control and research
Education and career
Are you interested in the exact cause of a myocardial or cerebral infarction or do you want to know how cardiac failure or arrhythmias develop? Or are you more interested in improving prevention or treatment of cardiovascular disease? Within the Center for Circulatory Health you can participate in solving these issues.
3584 CX Utrecht